SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of April 2005
FRESENIUS MEDICAL CARE CORPORATION
-----------------------------------------------
(Translation of registrant's name into English)
Else-Kroner Strasse 1
61346 Bad Homburg
Germany
----------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):____
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):____
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82
On April 6, 2005 certain officers of the Registrant will make
presentations to potential investors and investment analysts. The presentations
contain, among other things, forward-looking information about the Registrant
and its business. The slides that Registrant will use in these presentations
which contain forward looking statements are attached to this current report on
Form 6-K as Exhibit 99.1.
The slides contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are based upon our current
expectations, assumptions, estimates and projections about us and our industry
that address, among other things: our business development, operating
development and financial condition; our expectations of growth in the patient
population regarding renal dialysis products and services; our ability to remain
competitive in the markets for our products and services; changes in government
reimbursement policies and those of private payors; changes in pharmaceutical
administration patterns or reimbursement policies; foreign exchange
fluctuations; regulatory reforms; uncertainties in litigation or investigative
proceedings; the ability of financing; and other statements of our expectations,
beliefs, future plans and strategies, anticipated development and other matters
that are not historical facts. These and other factors affecting the company are
discussed in more detail in Fresenius Medical Care AG's reports filed with the
Securities and Exchange Commission, including without limitation, Fresenius
Medical Care AG's annual report on Form 20-F for the year ended December 31,
2004.
The Exhibit attached hereto, shall not be deemed "filed" for purposes
of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, regardless of any general incorporation language in such filing.
EXHIBITS
Exhibit 99.1 Presentation Slides
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DATE: April 6, 2005
FRESENIUS MEDICAL CARE
AKTIENGESELLSCHAFT
By: /s/ DR. BEN LIPPS
--------------------------------------
Name: Dr. Ben Lipps
Title: Chief Executive Officer and
Chairman of the Management Board
By: /s/ LAWRENCE A. ROSEN
--------------------------------------
Name: Lawrence A. Rosen
Title: Chief Financial Officer